Advertisement

Topics

Endocyte, Inc. Company Profile

22:46 EDT 21st September 2017 | BioPortfolio

Endocyte is a privately held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte’s advanced proprietary guided drug technology, the company is working to develop new drugs and diagnostic agents to treat many types of cancer and other serious diseases. The guided drug platform makes it possible to use highly potent drugs on extended and frequent dosing schedules and in combination with other drugs to maximize efficacy. The technology improves drug targeting and reduces the risk of side effects by combining drugs with ligands that are able to identify and attach to receptors found on tumor and other disease cells. Other clinical-stage products in the Endocyte pipeline include EC0225, a targeted combination of two potent anticancer drugs; EC0489, a targeted cancer drug; and EC17, a targeted immunotherapy agent.


News Articles [26 Associated News Articles listed on BioPortfolio]

Endocyte slumps on staff and R&D cuts

Shares hit an all-time low as Endocyte "refocuses" and slashes workforce.

Endocyte to cut workforce 40%

Endocyte, a provider developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, announced updates on clinical development for EC1456, its folate ...

Endocyte Axing 40% of Workforce, Scales Back Development of Two Cancer Candidates

Endocyte said today it will eliminate approximately 40% of its workforce—leaving it with 47 employees—under a restructuring that includes ending patient enrollment in a Phase I trial of one cancer...

Endocyte Axing 40% of Workforce, Scales Back Development of 2 Cancer Candidates

Endocyte said today it will eliminate approximately 40% of its workforce—leaving it with 47 employees—under a restructuring that includes ending patient enrollment in a Phase I trial of one cancer...

Active Wall Street: Blog Coverage: Endocyte to Present Posters on its Lead Clinical Stage Assets at the ASCO Annual Meeting

Upcoming AWS Coverage on Jazz Pharma Post-Earnings Results LONDON, UK / ACCESSWIRE / May 31, 2017 / Active Wall St. blog coverage looks at the headline from Endocyte, Inc. (NASDAQ: ECYT) as the Com...

Endocyte Cuts Workforce by 40 Percent After Clinical Trial Falters

Endocyte is halting a clinical trial for one of its cancer drugs and narrowing the focus of another following a review of the two early-stage drug programs, the company announced Friday. The changes a...

Endocyte Announces Clinical Updates for EC1456 and EC1169

- Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients -  - Refocusing Efforts on Chimeric Antigen Rece...

Endocyte to Present at the 2017 Cantor Global Healthcare Conference

WEST LAFAYETTE, Ind., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for pers...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Extension Study of EC145 for Subjects Enrolled in a Previous Study With EC145

This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 and have continuing evidence of cli...

Companies [4 Associated Companies listed on BioPortfolio]

Endocyte Incorporated

Endocyte, Inc is a biotechnology company focused on vitamin based drug targeting and delivery systems. Vitamins are essential components for specific biological cellular functions. Endocyte's mission ...

Endocyte, Inc.

Endocyte is a privately held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte’s advanced propr...

Endocyte

Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal h...

Merck and Endocyte

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines,...

More Information about "Endocyte, Inc." on BioPortfolio

We have published hundreds of Endocyte, Inc. news stories on BioPortfolio along with dozens of Endocyte, Inc. Clinical Trials and PubMed Articles about Endocyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endocyte, Inc. Companies in our database. You can also find out about relevant Endocyte, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record